UNSPSC 51101629: Trimetrexate

This classification denotes a folate antagonist and dihydrofolate reductase inhibitor, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier UPN4ITI8T4. European Medicines Agency schedules Trimetrexate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11312MIG. Trimetrexate generally arises in the molecular formula C19H23N5O3. The term TRIMETREXATE is an International Non-Proprietary Name or INN.

UNSPSC 51101629 Trimetrexate is a Commodity code that state and local governments use to procure pharmaceuticals and medical supplies, though recent activity shows the code capturing a broader range of health-related products including naloxone, first aid supplies, and generic pharmaceuticals through cooperative purchasing arrangements. State and local issuing bodies soliciting under this code span county health departments, municipal fire rescue divisions, state health and human services agencies, and multistate cooperative purchasing alliances. The work involves procurement of finished pharmaceutical products, emergency medical supplies, and OTC medications for use by public health facilities, emergency response divisions, and government employee health benefit programs, with vendors required to meet FDA compliance, cGMP certification, and drug supply chain security standards.

Recent activity includes Seminole County, Florida's IFB for 1,900 units of naloxone and 800 safe drug deactivation systems annually (due July 26, 2023), the City of Tampa's IFB for 169 line items of medical and first aid supplies for the Fire Department Rescue Division with a $700,000 estimated contract value and SLBE set-aside (due March 13, 2026), the Minnesota Multistate Cooperative Purchasing Alliance's RFP for generic multi-source pharmaceuticals and OTC products distributed through three authorized wholesalers with awards effective July 1, 2026 (due March 26, 2026), and the Texas Health and Human Services Commission's RFI regarding direct-to-manufacturer prescription fulfillment (due April 3, 2026). Geographic activity centers on Florida, Texas, and Minnesota, with multistate reach through MMCAP participation. The code shows a mix of routine medical supply procurement by local health and emergency response agencies and state-level strategic initiatives to optimize pharmacy benefit management and prescription fulfillment efficiency.